Sage Therapeutics scraps Parkinson’s drug development after treatment fails mid-stage study
Sage Therapeutics said on Wednesday it will stop development of its experimental drug to treat Parkinson’s disease after it failed a mid-stage study, sending the company’s shares down 4% before the bell.